Sequential metronidazole-furazolidone or clarithromycin-furazolidone compared to clarithromycin-based quadruple regimens for the eradication of Helicobacter pylori in peptic ulcer disease: a double-blind randomized controlled trial.

Abstract

BACKGROUND:

Furazolidone is a much cheaper drug with a very low resistance against Helicobacter pylori compared to clarithromycin. We aim to evaluate safety and efficacy of a sequential furazolidone-based regimen versus clarithromycin-based therapy in H. pylori eradication for ulcer disease.

MATERIALS:

Patients with proven peptic ulcer or duodenitis were randomized into three groups: OAB-M-F; metronidazole (M) (500 mg bid) for the first 5 days, followed by furazolidone (F) (200 mg bid) for the second 5 days; OAC-P; clarithromycin (C) (500 mg bid) for 10 days; and OAB-C-F; clarithromycin (500 mg bid) for the first 5 days and furazolidone (200 mg bid) for the second 5 days. All groups received omeprazole (O) (20 mg bid) and amoxicillin (A) (1 g bid). Groups OAB-M-F and OAB-C-F were also given bismuth subcitrate (B) (240 mg bid), whereas a placebo (P) was given to group OAC-P. Adverse events were scored and recorded. Two months after treatment, a C(13) -urea breath test was performed.

RESULTS:

Three hundred and ten patients were enrolled and 92 (OAB-M-F), 95 (OAC-P), and 98 (OAB-C-F) completed the study. The intention-to-treat eradication rates were 78.5% (95% CI = 69-85), 81.1% (95% CI = 73-88), and 82% (95% CI = 74-89), and per-protocol eradication rates were 91.3% (95% CI = 83-96), 90.4% (95% CI = 82-95), and 88.7% (95% CI = 81-94), for group OAB-M-F, OAC-P, and OAB-C-F, respectively. Eradication rate differences did not reach statistical significance. The most common adverse event, bad taste, occurred in all groups, but more frequently in groups OAC-P (34%) and OAB-C-F (32%), than OAB-M-F (14%) (p < .05). Adverse symptoms score were 0.88 ± 2.05 in group OAB-M-F, 1.15 ± 1.40 in group OAC-P, and 1.87 ± 1.62 in group OAB-C-F.

CONCLUSION:

Furazolidone can replace clarithromycin in H. pylori eradication regimens because of lack of development of resistance and very low cost.

• Authors: Saghi Riahizadeh, Reza Malekzadeh, Shahram Agah, Nasrin Zendehdel, Rasoul Sotoudehmanesh, Naser Ebrahimi-Dariani, Akram Pourshams, Homayoon Vahedi, Javad Mikaeli, Morteza Khatibian, Sadegh Massarrat
• Journal: Helicobacter (Helicobacter) Vol. 15 Issue 6 Pg. 497-504 (Dec 2010) ISSN: 1523-5378 [Electronic] England
• PMID: 21073605 (Publication Type: Journal Article, Randomized Controlled Trial)
• Copyright: © 2010 Blackwell Publishing Ltd.

Chemical References

• Anti-Bacterial Agents
• Metronidazole
• Furazolidone
• Clarithromycin

Topics

• Adolescent
• Adult
• Aged
• Aged, 80 and over
• Anti-Bacterial Agents (administration & dosage, adverse effects)
• Clarithromycin (administration & dosage, adverse effects)
• Double-Blind Method
• Drug Administration Schedule
• Drug Therapy, Combination
• Female
• Furazolidone (administration & dosage, adverse effects)
• Helicobacter Infections (drug therapy, microbiology)
• Helicobacter pylori (drug effects, physiology)
• Humans
• Male
• Metronidazole (administration & dosage, adverse effects)
• Middle Aged
• Peptic Ulcer (drug therapy, microbiology)
• Young Adult